NCT05351697 2026-03-17
BR105-I
BioRay Pharmaceutical Co., Ltd.
Phase 1 Terminated
Clinical Trials
6 trialsNCT05987605 2025-02-19
Phase I/II Clinical Study of 1A46 Drug Substance
BioRay Pharmaceutical Co., Ltd.
Phase 1 Terminated
NCT04949191 2024-09-19
The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.
Incyte Corporation
Phase 2 Terminated
NCT05048134 2024-09-19
A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Terminated
NCT00724425 2015-04-15
A Phase 1 Dose Escalation Study of IPI-493
Infinity Pharmaceuticals, Inc.
Phase 1 Terminated
NCT00652158 2013-09-23
A Phase 1 Trial of Extended MLN8054 Dosing in Patients With Advanced Malignancies
Millennium Pharmaceuticals, Inc.
Phase 1 Terminated